A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.
No-one can say England's Accelerated Access Review, which aims to “ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations" isn't aiming high, writes Leela Barham.
As pharma continues to move towards "beyond the pill" strategies, better understanding of patients' sometimes paradoxical view of disease can help lead to strategies for helping them live more productive lives, writes Nick Hicks.
Last week, the White House nominated Robert Califf to head FDA, long after he came to the agency in January 2015 as deputy commissioner for medical products and tobacco. But will he be confirmed, asks Jill Wechsler.
UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.
The issue of drug price controls in public prescription programs has long been a point of contention. But today, writes Tom Norton, as several historical and contemporary factors continue to line up, we may be on a pathway to changing that.